Abbvie turnover at all-time high

Quote
AbbVie and Alkermes reps have been jumping ship and running to BMS. High bases sound attractive right now but theyre going to get their arses kicked when Emraclidine comes next year. No constipation and qd dosing. BMS doesn’t have time to recoup their $15B.
 






anonymous said:
AbbVie and Alkermes reps have been jumping ship and running to BMS. High bases sound attractive right now but theyre going to get their arses kicked when Emraclidine comes next year. No constipation and qd dosing. BMS doesn’t have time to recoup their $15B.
Click to expand...
BMS has plans for QD and injectable as well along with other indications. They won’t let this flop.
 


















anonymous said:
By the time that happens they’ll be one of 3 agents on the market with similar mechanisms. Good luck.
Click to expand...
Great, wonderful! Glad there will be more options for those living with Schizophrenia.
Back to the original post though…. Why is the turnover in psych division at an all time high especially in the northeast? These managers interview for these roles then don’t pick anyone to fill the spots and leave them open for months and months.
 
























anonymous said:
Why are so many leaving? The Humira gravy train is over. Now you're left with micro-managing primary care company with no new ideas and the lowest morale in it's history both in HO and the field.
Click to expand...
This is spot on, the follow ons to Humira have too much pressure to perform while the competition increases exponentially every few years.
 






Fact Check: 2023 industry audit revealed that Abbvie employees stayed at their company 1.5X longer than big pharma peers and 6X longer than biotechs. Fortunately, people like working for Abbvie!
 






anonymous said:
Fact Check: 2023 industry audit revealed that Abbvie employees stayed at their company 1.5X longer than big pharma peers and 6X longer than biotechs. Fortunately, people like working for Abbvie!
Click to expand...
Not really a great stat considering most people stay at a company for about 2 years these days. Oh and biotechs usually get bought quick if they are good. No one really likes working at big pharma. We just put up with it.
 


















Why does ZS tell senior management that multiple reps per territory is a good idea? The answer is that we pay ZS millions for this advice and then swamp the trenches with so many people that offices are selecting who they want to see
 






anonymous said:
Why does ZS tell senior management that multiple reps per territory is a good idea? The answer is that we pay ZS millions for this advice and then swamp the trenches with so many people that offices are selecting who they want to see
Click to expand...
Why? Because our decision-makers are clueless and fall for the ZS game of three-card monte: in less than 5 years, we will give ZS another several million to tell us to reduce head count. It's an old pharma shell game that they play. And it works!!! Well, it works for ZS.
 






anonymous said:
Why? Because our decision-makers are clueless and fall for the ZS game of three-card monte: in less than 5 years, we will give ZS another several million to tell us to reduce head count. It's an old pharma shell game that they play. And it works!!! Well, it works for ZS.
Click to expand...
Of course ZS over populates sales forces. They are all from New Dehli. One of the most overpopulated over polluted swamps on the planet and its all those people know
 


















The trifecta of ding dong, preclinical device and angry kangaroo couldn’t build a pipeline beyond an intestine full of feces. Why would anyone want to stay for this $#itshow?
 












Top Bottom
Back
Quote